Novartis AG (NVS)

74.61
NYSE : Health Care
Prev Close 74.61
Day Low/High 0.00 / 0.00
52 Wk Low/High 66.93 / 83.58
Avg Volume 2.86M
Exchange NYSE
Shares Outstanding 2.37B
Market Cap 174.26B
EPS 2.80
P/E Ratio 26.03
Div & Yield 2.72 (3.70%)

Latest News

Weekly Roundup

Earnings and hopes for a tax plan help lift the markets. Portfolio moves include exiting a utility position.

Updates on Some Names in Our Portfolio

Taking a look at Facebook, Arconic, Magellan and others.

Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps

Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps

The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite Pharma's competing "CAR-T" KTE-C19 in the same DLBCL patients.

Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait

Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait

The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite's competing 'CAR-T' KTE-C19 in the same DLBCL patients.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials

Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials

Novartis shares fell after it said a potentially key cardiovascular treatment had failed a global clinical trial, putting doubt over the group's ability to offset slowing heart disease drug sales.

Chaos Is Biggest Threat to Wednesday's Vote on Repealing Obamacare

Chaos Is Biggest Threat to Wednesday's Vote on Repealing Obamacare

The Democrats aim to generate public opposition to repeal by offering amendments that highlight fears the GOP plan will result in more expensive insurance and fewer people with coverage.

Stocks Fall for Day Two as Trump Targets Health Care Sector

Stocks Fall for Day Two as Trump Targets Health Care Sector

Stocks fall for a second day on Tuesday, the first back-to-back decline since January, as a selloff in health care spoils attempts by the market to push higher.

Stocks Slide as Health Care Sector Weighs on Wall Street

Stocks Slide as Health Care Sector Weighs on Wall Street

Stocks slump Tuesday as a selloff in health care spoils an attempt by the market to push higher.

Drugmakers Suffer After Trump Tweet

Drugmakers Suffer After Trump Tweet

Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.

Stocks Fluctuate as Wall Street Digests Health Care Moves From Washington

Stocks Fluctuate as Wall Street Digests Health Care Moves From Washington

Stocks are in flux on Tuesday as Donald Trump makes vague promises to lower drug prices, while Republicans unveil their bill to tackle health care reform.

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European Health Care Stocks Wobble After Trump Tweet on Drug Prices

European healthcare stocks fell Tuesday after President Donald Trump reiterated a vow to reduce drug prices in the United States.

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

Trump's Anti-Pot Stance Won't Hurt This 'Canna-Business' Stock

President Trump's socially conservative administration has vowed to crack down on marijuana, but here's why pot investors shouldn't worry.

Novartis Shares Lower on Ex Dividend Trading, Reports of Kickbacks Fine In South Korea

Novartis Shares Lower on Ex Dividend Trading, Reports of Kickbacks Fine In South Korea

Novartis shares fell in Zurich Thursday after it had the sales of some of its drugs banned in South Korea following a fine from food and drug safety officials.

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite Pharma CAR-T Cancer Therapy Shows Strong, Durable Effect in Lymphoma Patients

Kite intends to submit a marketing application for KTE-C19 to the U.S. Food and Drug Administration by the end of March.

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's $900 Billion Sovereign Wealth Fund Rebounds in 2016 With 8.7% Equity Surge

Norway's sovereign wealth fund, the world's biggest and a key investor in Apple and Alphabet, earned more than $53 billion last year as equity returns surged.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Novartis Shows the World a Take of 2 Charts

Novartis Shows the World a Take of 2 Charts

Novartis has seen some very aggressive buying the past five months -- time to join in.

Ring the Register With These Upcoming Spinoffs

Ring the Register With These Upcoming Spinoffs

Numerous studies show that corporate carve outs deliver robust returns.

Bristol-Myers Buys Back Shares, Shuffles Board

Bristol-Myers Buys Back Shares, Shuffles Board

The drug company will carry out 80% of a $2B repurchase by Feb. 28 after pressure from insurgent Jana Partners. Icahn also reportedly acquired a stake, with focus on M&A.

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Propeller Health Enters Into Collaboration To Connect Breezhaler™ Devices To The Propeller Platform

Propeller Health Enters Into Collaboration To Connect Breezhaler™ Devices To The Propeller Platform

Partnership adds another important family of leading respiratory brands and solidifies Propeller's position as the leading digital platform in respiratory medicine

Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment

Cellectis is taking another step to move immunotherapy 'off the shelf.'

Mallinckrodt Divests Drug Delivery Unit as Shedding Continues

Mallinckrodt Divests Drug Delivery Unit as Shedding Continues

The pharmaceutical company has signed a deal to sell its intrathecal therapy segment to a Piramal Enterprises subsidiary for up to $203 million.